Steg AD - Search Results

1

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN. Steg AD, et al. Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142828 Free PMC article.

2

Smoothened antagonists reverse taxane resistance in ovarian cancer.

Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD, Landen CN. Steg AD, et al. Mol Cancer Ther. 2012 Jul;11(7):1587-97. doi: 10.1158/1535-7163.MCT-11-1058. Epub 2012 May 2. Mol Cancer Ther. 2012. PMID: 22553355 Free PMC article.

3

Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Ziebarth AJ, et al. Among authors: steg ad. Clin Cancer Res. 2013 Jan 1;19(1):170-82. doi: 10.1158/1078-0432.CCR-12-1045. Epub 2012 Nov 12. Clin Cancer Res. 2013. PMID: 23147994 Free PMC article.

4

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN. Dobbin ZC, et al. Among authors: steg ad. Oncotarget. 2014 Sep 30;5(18):8750-64. doi: 10.18632/oncotarget.2373. Oncotarget. 2014. PMID: 25209969 Free PMC article.

5

Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.

Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH, Landen CN. Steg AD, et al. Oncotarget. 2014 Aug 30;5(16):7065-80. doi: 10.18632/oncotarget.2295. Oncotarget. 2014. PMID: 25216523 Free PMC article.

6

Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.

Cornelison R, Dobbin ZC, Katre AA, Jeong DH, Zhang Y, Chen D, Petrova Y, Llaneza DC, Steg AD, Parsons L, Schneider DA, Landen CN. Cornelison R, et al. Among authors: steg ad. Clin Cancer Res. 2017 Nov 1;23(21):6529-6540. doi: 10.1158/1078-0432.CCR-17-0282. Epub 2017 Aug 4. Clin Cancer Res. 2017. PMID: 28778862 Free PMC article.

7

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.

Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK. Landen CN Jr, et al. Among authors: steg ad. Mol Cancer Ther. 2010 Dec;9(12):3186-99. doi: 10.1158/1535-7163.MCT-10-0563. Epub 2010 Oct 1. Mol Cancer Ther. 2010. PMID: 20889728 Free PMC article.

8

Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Steg AD, et al. Clin Cancer Res. 2011 Sep 1;17(17):5674-85. doi: 10.1158/1078-0432.CCR-11-0432. Epub 2011 Jul 13. Clin Cancer Res. 2011. PMID: 21753153 Free PMC article.

9

The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses.

Booker BE, Steg AD, Kovac S, Landen CN, Amm HM. Booker BE, et al. Among authors: steg ad. Cancer Biol Ther. 2020 Oct 2;21(10):873-883. doi: 10.1080/15384047.2020.1806640. Epub 2020 Sep 11. Cancer Biol Ther. 2020. PMID: 32914706 Free PMC article.

10

Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.

Steg A, Amm HM, Novak Z, Frost AR, Johnson MR. Steg A, et al. Cancer Biol Ther. 2010 Nov 1;10(9):893-902. doi: 10.4161/cbt.10.9.13252. Epub 2010 Nov 1. Cancer Biol Ther. 2010. PMID: 20814245 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page